Newsroom
We’re Delivering the Promise of Healthier Lives.
quick links
Featured News
CURE PHARMACEUTICAL
Press Releases
CURE Pharmaceutical Letter to Shareholders
Investment in New Marketing Strategies Showing Encouraging Early Results Enhanced Instagram & Media campaigns featuring Nicole Kidman highlighting Seratopical Revolution Incubator Strategy Initiated with New Market Disruptor Products arriving 1H2023 SHERMAN OAKS, CA / December 15, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) CEO Nancy Duitch is providing an update to its shareholders on positive […]
CURE Pharmaceutical Reports Third Quarter 2022 Results With Strong Sequential and Year Over Year Revenue Increases and Continued High Margins
New Marketing Programs Showing Encouraging Early Results SHERMAN OAKS, CA / November 22, 2022 / CURE Pharmaceutical Holding Corp. (OTCQB:CURR) (“CURE” or the “Company”), a proprietary broad platform technology and wellness company, today announced results for the quarter ended September 30, 2022. Key operational highlights included the following: Revenue in the third quarter surged 32.1% […]
Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV
Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern) Oxnard, California – Cure Pharmaceutical Holding Corp. (OTCQB: CURR) (“CURE”), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems, announced today that it will be presenting at the 12th annual Invitational on Tuesday October 25 at […]
Cure Pharmaceutical Reports Second Quarter 2022 Results With Increased Sequential Revenues and Strong Margins
Balance Sheet and Governance Strengthened with Asset Sale and Board Appointments New Marketing Programs Showing Encouraging Early Results OXNARD, Calif., Sept. 02, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary broad platform and wellness technology company, today announced results for the quarter ended June 30, 2022. Key operational highlights included the following: […]
CURE Pharmaceutical Announces Rob Davidson as new Chairman of the Board and Appointment of Rob Costantino as Member of the Board and Audit Committee Chairman
Rob Davidson brings a deep understanding of CURE pipeline, provides expertise in continued new product development, patent creation and continuity in non-dilutive on-going deal transactions and years of public company experience. Rob Costantino brings a unique combination of decades of financial expertise, investing experience and shareholder advocacy, operational experience, and many years of negotiating success […]
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
OXNARD, Calif., Aug. 09, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company hosted a shareholder call on Wednesday, August 3, 2022. On the recorded call/webcast, the executive management team provided details on the recent $20 million non-dilutive sale of a portion of its product […]
CURE Pharmaceutical Announces the Appointment of New Board Member
Gerald Bagg brings deep understanding of CPG to CURE OXNARD, Calif., Aug. 02, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced the appointment of Gerald Bagg to its board of directors. This strategic addition adds depth in CPG and advertising and brings the number of board members […]
CURE Pharmaceutical Announces Teleconference With Investors
Updates on Recent Transaction and Business will be Provided OXNARD, Calif., Aug. 01, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that the Company will be hosting a teleconference with management on Wednesday, August 3, 2022, at 4:00 pm Eastern Time to discuss the recent $20 […]
CURE Pharmaceutical Announces the Sale of a Portion of its Platform Technology IP for $20 Million
Proceeds Will Be Used to Grow CURE’s Wellness and Beauty Brands and Its Remaining Proprietary Platform Technology OXNARD, Calif., July 28, 2022 — CURE Pharmaceutical Holding Corp. (OTC: CURR) (“CURE”), a proprietary platform technology company, today announced that it has sold a portion of its platform technology intellectual property and related assets for $20 million […]
CURE Pharmaceutical Announces Positive Findings from Study at Cincinnati Children’s Hospital Medical Center (CCHMC) Using CURE’s Proprietary, Oral Thin Film (OTF) High, Single Dose Vitamin D in Pediatric Patients Pre- and Post-Hematopoietic Stem Cell Transplantation (HSCT)
CURE’s Patented and Proprietary OTF Vitamin D Found to be More Effective than Standard Supplementation in Achieving pre- and post-Surgery Vitamin D Sufficiency Necessary to Reduce Immune-Mediated Damage such as Graft Versus Host Disease (GVHD) CCHMC to Seek Formulary approval for CURE’s OTF Vitamin D Supplement in its Hospital Formulary OXNARD, Calif., May 12, 2022 […]